ArticlePloS one2018
Anal cancer in high-income countries: Increasing burden of disease.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.
- The impact of anal cancer treatment on female sexuality and intimacy: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Pooled it
- Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.The lancet. Gastroenterology & hepatology · 2022Trial
- Premature mortality and years of potential productive life lost due to HPV-attributable cancers in Brazil and Mexico: 2011 Versus 2023.Human vaccines & immunotherapeutics · 2026Article
- Assessing the burden of HPV-associated cancers in Brazil: Hospitalization and mortality trends from 2011 to 2019.Human vaccines & immunotherapeutics · 2026Article
- Simultaneous integrated boost vs sequential boost chemoradiotherapy in anal squamous cell carcinoma: Association with improved disease-free survival and the role of treatment delivery parameters.Clinical and translational radiation oncology · 2026Article
- Incidence and burden of anal cancer-time to fight the growing disparities.ESMO gastrointestinal oncology · 2026Review
- An overview of clinical trials in anal cancer 1999-2024.ESMO gastrointestinal oncology · 2026Article
- Causative Human Papillomavirus (HPV) Genotypes of Anal Cancers in Australian Cisgender Women.Journal of medical virology · 2026Article
- Genotypes of human papillomavirus and clinical pathological features among patients with anal carcinoma in North-western Tanzania.Infectious agents and cancer · 2026Article
- An international multi-centre study to develop and validate federated learning-based prognostic models for anal cancer.Nature communications · 2026Article
- Integrating PET and MRI Radiomics for Staging and Prognostic Stratification in Anal Canal Cancer.Cancers · 2025Article
- Anal cancer screening and the role of clinicians providing gynecologic care: A survey of anal cancer screening knowledge and practice patterns at an urban tertiary medical center in the United States.Preventive medicine reports · 2025Article
- Age-specific trends in colorectal, appendiceal, and anal tumour incidence by histological subtype in Australia from 1990 to 2020: a population-based time-series analysis.The Lancet regional health. Western Pacific · 2025Article
- Anal Cancer Incidence Rates Among Men and Women With and Without HIV in South Africa.Open forum infectious diseases · 2025Article
- Interstitial HDR brachytherapy for anal cancer-results and quality of life.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Understanding HPV-Induced Cancers and Investigating the Barriers Faced by Low- and Middle-Income Countries in Prevention and Treatment.International journal of molecular sciences · 2025Review
- Age-specific trends in colorectal, appendiceal, and anal tumour incidence by histological subtype in Australia from 1990 to 2020: a population-based time-series analysis.medRxiv : the preprint server for health sciences · 2025Article
- Clinicopathological Features by Differentiation and Prognostic Factors in Anal Canal Carcinoma.Journal of the anus, rectum and colon · 2025Article
- Screening of Anal HPV Precancerous Lesions: A Review after Last Recommendations.Journal of clinical medicine · 2024Review
- Sexual risk characteristics, social vulnerability, and anal cancer screening uptake among men living with HIV in the deep south.AIDS care · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have reported that anal cancer incidence has increased in individual countries; however, age-specific trends were not examined in detail. This study describes pooled and country-specific anal cancer incidence trends by sex, age (all ages, <60 and 60+ years) and histological subtype (all subtypes, squamous cell carcinoma [SCC] and adenocarcinoma [ADC]).
methodsFive-year incidence and population-at-risk data were obtained from IARC's Cancer Incidence in Five Continents for the years 1988-1992 to 2008-2012. The standardised rate ratios (SRRs) for 2008-2012 vs 1988-1992 and the 5-year average percent change (AvPC) during the period were used to assess changes in the age-standardised incidence rates.
resultsDuring the study period, there were significant increases in the incidence of SCC in both men and women of all age groups with significant increasing trend, and these increases were highest in those aged <60 years (SRR = 2.34 [95% CI:2.11-2.58] in men and SRR = 2.76 [95% CI:2.54-3.00] in women). By contrast, there were significant decreases in the incidence of ADC in men and women of all ages (SRR = 0.60 [95% CI:0.54-0.67]) and (SRR = 0.63 [95% CI:0.56-0.71], respectively), with similar decreases in those aged <60 years and 60+ years. These competing trends still resulted in significant increases in the overall incidence of anal cancer in men and women of all ages groups with significant increasing trend. The SRRs in men of all ages, <60 years and 60+ years were 1.35 (95% CI:1.28-1.42), 1.77 (95% CI:1.62-1.92) and 1.08 (95% CI:1.00-1.15), respectively. The corresponding SRRs in women were 1.75 (95% CI:1.67-1.83), 2.31 (95% CI:2.14-2.48) and 1.38 (95% CI 1.31-1.46), respectively.
conclusionIncreases in the incidence of anal SCC has driven an overall increase in anal cancer incidence; this may be associated with changing sexual behaviours and increasing levels of HPV exposure in younger cohorts. The findings further reinforce the importance of HPV vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.